Sunday , February 25 2018
Home / Therapies / SGLT-2 Therapy Center (page 18)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Surprising Trends in the Use of Antidiabetic Drugs

Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …

Read More »

John Anderson, MD, Q3: What is the ADA doing about prevention of diabetes and prediabetes?

John-Anderson

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

Read More »

Obesity 2014, Part 7

DCMS180HS

Dr. Stanley Schwartz finishes up his slides series on the current state of the obesity epidemic and its relationship with diabetes. Topics covered in this set include a discussion of the newest drug therapies on the market including the incretins and the SGLT-2 inhibitors…. To download in PowerPoint (.ppt) format:¬†Obesity …

Read More »

FDA Puts Empagliflozin on Hold

Quality issues in the manufacturing plant prevents final approval…. The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week. Eli Lilly and Boehringer Ingelheim said the FDA had issued a complete response …

Read More »